These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 30647052)

  • 1. BCL2/MDM2 Inhibitor Combo Effective in AML.
    Cancer Discov; 2019 Feb; 9(2):156. PubMed ID: 30647052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
    Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
    J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma.
    Van Goethem A; Yigit N; Moreno-Smith M; Vasudevan SA; Barbieri E; Speleman F; Shohet J; Vandesompele J; Van Maerken T
    Oncotarget; 2017 Aug; 8(34):57047-57057. PubMed ID: 28915653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 summary of plasma concentration-QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML.
    Blotner S; Chen LC; Ferlini C; Zhi J
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):597-607. PubMed ID: 29392451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCL2 Inhibition by Venetoclax: Targeting the Achilles' Heel of the Acute Myeloid Leukemia Stem Cell?
    Pullarkat VA; Newman EM
    Cancer Discov; 2016 Oct; 6(10):1082-1083. PubMed ID: 27698099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.
    Konopleva M; Pollyea DA; Potluri J; Chyla B; Hogdal L; Busman T; McKeegan E; Salem AH; Zhu M; Ricker JL; Blum W; DiNardo CD; Kadia T; Dunbar M; Kirby R; Falotico N; Leverson J; Humerickhouse R; Mabry M; Stone R; Kantarjian H; Letai A
    Cancer Discov; 2016 Oct; 6(10):1106-1117. PubMed ID: 27520294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
    Ram R; Amit O; Zuckerman T; Gurion R; Raanani P; Bar-On Y; Avivi I; Wolach O
    Ann Hematol; 2019 Aug; 98(8):1927-1932. PubMed ID: 31187237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
    Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
    Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
    Nemunaitis J; Young A; Ejadi S; Miller W; Chen LC; Nichols G; Blotner S; Vazvaei F; Zhi J; Razak A
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):529-537. PubMed ID: 29368050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report.
    Liu B; Narurkar R; Hanmantgad M; Zafar W; Song Y; Liu D
    Front Med; 2018 Oct; 12(5):593-599. PubMed ID: 29785506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
    Seymour JF; Kipps TJ; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Gerecitano J; Robak T; De la Serna J; Jaeger U; Cartron G; Montillo M; Humerickhouse R; Punnoose EA; Li Y; Boyer M; Humphrey K; Mobasher M; Kater AP
    N Engl J Med; 2018 Mar; 378(12):1107-1120. PubMed ID: 29562156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias.
    Wojcik I; Szybka M; Golanska E; Rieske P; Blonski JZ; Robak T; Bartkowiak J
    Neoplasma; 2005; 52(4):318-24. PubMed ID: 16059649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
    Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
    Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDM2- and FLT3-inhibitors in the treatment of
    Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T
    Haematologica; 2018 Nov; 103(11):1862-1872. PubMed ID: 29976747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition.
    Sharma P; Pollyea DA
    Curr Hematol Malig Rep; 2018 Aug; 13(4):256-264. PubMed ID: 29982865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review.
    Short NJ; Ravandi F
    Expert Rev Hematol; 2016 Jun; 9(6):529-34. PubMed ID: 27158854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.
    Reis B; Jukofsky L; Chen G; Martinelli G; Zhong H; So WV; Dickinson MJ; Drummond M; Assouline S; Hashemyan M; Theron M; Blotner S; Lee JH; Kasner M; Yoon SS; Rueger R; Seiter K; Middleton SA; Kelly KR; Vey N; Yee K; Nichols G; Chen LC; Pierceall WE
    Haematologica; 2016 May; 101(5):e185-8. PubMed ID: 26869629
    [No Abstract]   [Full Text] [Related]  

  • 19. Combined venetoclax and alvocidib in acute myeloid leukemia.
    Bogenberger J; Whatcott C; Hansen N; Delman D; Shi CX; Kim W; Haws H; Soh K; Lee YS; Peterson P; Siddiqui-Jain A; Weitman S; Stewart K; Bearss D; Mesa R; Warner S; Tibes R
    Oncotarget; 2017 Dec; 8(63):107206-107222. PubMed ID: 29291023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venetoclax: A new wave in hematooncology.
    Mihalyova J; Jelinek T; Growkova K; Hrdinka M; Simicek M; Hajek R
    Exp Hematol; 2018 May; 61():10-25. PubMed ID: 29477371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.